Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1007/s10723-010-9171-y | Architectural Requirements for Cloud Computing Systems: An Enterprise Cloud Approach |
| https://doi.org/10.1016/j.arr.2010.04.005 | Geriatric drug therapy: Neglecting the inevitable majority |
| https://doi.org/10.1208/s12248-013-9533-z | How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider |
| https://doi.org/10.1109/tvt.2023.3237173 | Toyota Mirai: Powertrain Model and Assessment of the Energy Management |
| https://doi.org/10.1016/j.ejps.2012.10.021 | Developing and advancing dry powder inhalation towards enhanced therapeutics |
| https://doi.org/10.1016/j.ijpharm.2013.11.024 | Public engagement workshop: How to improve medicines for older people? |
| https://doi.org/10.1016/j.ijpharm.2013.07.038 | Meeting commentary—“Medicines for older adults: Learning from practice to develop patient centric drug products” |
| https://doi.org/10.5964/miss.14067 | Going global: 39 language versions of the BFI-2-XS |
| https://doi.org/10.1177/10915818221101788 | Repeated-Dose Toxicity, Biodistribution, and Shedding Assessments With a ChAd155 Respiratory Syncytial Virus Vaccine Candidate Evaluated in Rabbits and Rats |
| https://doi.org/10.1007/978-3-031-90951-1_8 | Translation in Computer-Based International Large-Scale Assessment: Not a Stand-Alone Component |
| https://doi.org/10.1016/j.ejps.2011.09.012 | Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products |
| https://doi.org/10.1108/00012530610692348 | Benchmarking e‐government policy within the e‐Europe programme |
| https://doi.org/10.1109/hicss.2007.68 | An Interoperability Framework for Pan-European E-Government Services (PEGS) |
| https://doi.org/10.1080/09511928908944387 | CIM-OSA: computer integrated manufacturing—open system architecture |
| https://doi.org/10.1007/s00391-012-0361-z | Challenges and opportunities in the design of age-appropriate drug products |
| https://doi.org/10.1016/0166-3615(94)00043-p | Positioning of modelling approaches, methods and tools |
| https://doi.org/10.1007/978-3-319-43099-7_17 | Considerations for Topical and Transdermal Drug Delivery in Older Adults |
| https://doi.org/10.1002/jcph.1024 | Improving Therapeutics to Better Care for Older Adults and the Young: Report From the American College of Clinical Pharmacology Workshop |
| https://doi.org/10.1007/978-1-4614-1004-1_13 | Coated Multiparticulates for Controlling Drug Release |
| https://doi.org/10.1007/978-3-319-43099-7_11 | The Expectation to Treatment Model: A Framework for Adherence and Effectiveness |
| https://doi.org/10.1007/978-3-319-43099-7_13 | Defining Patient Centric Drug Product Design and Its Impact on Improving Safety and Effectiveness |
| https://doi.org/10.1007/978-3-662-38009-3_21 | CIM-OSA, a computer integrated manufacturing based on the open system approach |
| https://doi.org/10.1002/9781394230600.ch4 | Class‐Imbalanced Problems in Malware Analysis and Detection in Classification Algorithms |
| https://doi.org/10.1007/978-3-319-43099-7_37 | Opportunities in Drug Product Development in an Aging Population |
| https://doi.org/10.1007/978-3-319-43099-7_9 | Patient Reported Outcomes in Clinical Trials and Practice with Older Patients |
| https://doi.org/10.1007/978-3-319-43099-7_7 | Patients’ Clinical Characteristics, Disease Experience, and Perception |